FDA Expands AstraZeneca (AZN) Lynparza Label in Prostate Cancer
ソース:
NASDAQ Stocks
/
02 6 2023 14:10:44 America/New_York
AstraZeneca AZN and Merck MRK announced that the FDA approved the expansion of their PARP inhibitor Lynparza (olaparib) in prostate cancer indication https://www.nasdaq.com/articles/fda-expands-astrazeneca-azn-lynparza-label-in-prostate-cancer
シェアする